Search

Background: Most data on mortality and prognostic factors in patients with heart failure come from North America and Europe, with little information from other regions. Here, in the International Congestive Heart Failure (INTER-CHF) study, we aimed to measure mortality at 1 year in patients with heart failure in Africa, China, India, the Middle East, southeast Asia and South America; we also explored demographic, clinical, and socioeconomic variables associated with mortality. Methods: We enrolled consecutive patients with heart failure (3695 [66%] clinic outpatients, 2105 [34%] hospital in patients) from 108 centres in six geographical regions. We recorded baseline demographic and clinical characteristics and followed up patients at 6 months and 1 year from enrolment to record symptoms, medications, and outcomes. Time to death was studied with Cox proportional hazards models adjusted for demographic and clinical variables, medications, socioeconomic variables, and region. We used the explained risk statistic to calculate the relative contribution of each level of adjustment to the risk of death. Findings: We enrolled 5823 patients within 1 year (with 98% follow-up). Overall mortality was 16·5%: highest in Africa (34%) and India (23%), intermediate in southeast Asia (15%), and lowest in China (7%), South America (9%), and the Middle East (9%). Regional differences persisted after multivariable adjustment. Independent predictors of mortality included cardiac variables (New York Heart Association Functional Class III or IV, previous admission for heart failure, and valve disease) and non-cardiac variables (body-mass index, chronic kidney disease, and chronic obstructive pulmonary disease). 46% of mortality risk was explained by multivariable modelling with these variables; however, the remainder was unexplained. Interpretation: Marked regional differences in mortality in patients with heart failure persisted after multivariable adjustment for cardiac and non-cardiac factors. Therefore, variations in mortality between regions could be the result of health-care infrastructure, quality and access, or environmental and genetic factors. Further studies in large, global cohorts are needed. Funding: The study was supported by Novartis.

The type 2 diabetes mellitus is considering as metabolic disorder, the unfavourable long-term outcomes and closely associated with chronic inflammation. The present study investigated to explore the association of interleukin-6 and uric acid in patients with type 2 diabetes mellitus and coronary artery disease. Newly diagnosed CAD patients with T2DM (100) and T2DM and CAD patients after 5 years (100) underwent detailed anthropometric, demographic, biochemical and experimental characterization. The serum levels of interleukin 6 were measured by enzyme linked immuno-sorbent assay. The T2DM and CAD patients after 5 years had significant higher circulating levels of interleukin 6 and significant decreased levels of uric acid. The newly diagnosed CAD patients with T2DM had significant higher circulating levels of interleukin 6. Significant positive correlation was found between fat mass and IL-6, and negative correlation with uric acid and IL-6, (P<0.05). The both the groups of T2DM with CAD patients shown significantly elevated levels of interleukin 6, based on this findings interleukin 6 might be used as early predictable and prognostic marker for CAD in patients with T2DM., (© 2023 Biomedical Informatics.)